Krystal Biotech, Inc. (KRYS)
341.78
-4.80
(-1.39%)
USD |
NASDAQ |
Aug 24, 16:00
341.78
0.00 (0.00%)
After-Hours: 19:57
Krystal Biotech Total Liabilities (Quarterly) : 141.52M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 141.52M |
| March 31, 2026 | 120.24M |
| December 31, 2025 | 114.23M |
| September 30, 2025 | 102.22M |
| June 30, 2025 | 97.75M |
| March 31, 2025 | 89.74M |
| December 31, 2024 | 109.46M |
| September 30, 2024 | 96.47M |
| June 30, 2024 | 78.76M |
| March 31, 2024 | 54.05M |
| December 31, 2023 | 39.71M |
| September 30, 2023 | 34.40M |
| June 30, 2023 | 30.91M |
| March 31, 2023 | 42.28M |
| December 31, 2022 | 36.22M |
| September 30, 2022 | 35.61M |
| June 30, 2022 | 42.14M |
| March 31, 2022 | 68.32M |
| December 31, 2021 | 32.72M |
| September 30, 2021 | 42.86M |
| Date | Value |
|---|---|
| June 30, 2021 | 25.02M |
| March 31, 2021 | 12.37M |
| December 31, 2020 | 18.76M |
| September 30, 2020 | 9.731M |
| June 30, 2020 | 8.449M |
| March 31, 2020 | 6.762M |
| December 31, 2019 | 6.109M |
| September 30, 2019 | 6.586M |
| June 30, 2019 | 6.866M |
| March 31, 2019 | 6.218M |
| December 31, 2018 | 2.89M |
| September 30, 2018 | 2.161M |
| June 30, 2018 | 0.759M |
| March 31, 2018 | 0.452M |
| December 31, 2017 | 0.64M |
| September 30, 2017 | 2.475M |
| June 30, 2017 | 4.806M |
| March 31, 2017 | 2.265M |
| December 31, 2016 | 1.893M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Marker Therapeutics, Inc. | 2.42M |
| TG Therapeutics, Inc. | 1.036B |
| Tenaya Therapeutics, Inc. | 24.13M |
| Cytokinetics, Inc. | 2.098B |
| Vericel Corp. | 132.82M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.501B |
| Shareholders Equity (Quarterly) | 1.359B |
| Debt to Equity Ratio | 0.0065 |
| Current Ratio | 8.318 |
| Net Debt Paydown Yield | 0.00% |